<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02797288</url>
  </required_header>
  <id_info>
    <org_study_id>18782</org_study_id>
    <secondary_id>R01AI124214-01</secondary_id>
    <nct_id>NCT02797288</nct_id>
  </id_info>
  <brief_title>Immune Response to FMT for C.Difficile</brief_title>
  <official_title>Role of Eosinophils in Innate Protection From C. Difficile</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The protocol aims to address the basic mechanisms of Clostridium difficile pathogenesis by
      identifying how Clostridium difficile toxins inhibit eosinophils that otherwise would protect
      the gut from damage. This could lead to new and effective approaches to the treatment or
      prevention of Clostridium difficile colitis that act downstream of fecal microbiota
      transplants (FMT) or next generation probiotics. Successful fecal transplantation will
      restore Interleukin-25, Interleukin-4 and eosinophils to the colon
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Biopsies will be obtained from random areas of the sigmoid colon in subjects at the time of
      fecal transplantation. Follow-up biopsies will be obtained from the sigmoid colon during
      convalescence 60 days after fecal transplant for subjects who agree to return for optional 60
      day follow-up. Biopsies taken for research purposes at each colonoscopy will be analyzed for:
      cytokines and chemokines, gene expression analysis, immunohistochemistry and high dimensional
      flow-cytometry.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 22, 2017</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>tissue IL-25</measure>
    <time_frame>0-60 days post fecal transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tissue IL-4</measure>
    <time_frame>0-60 days post fecal transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue IL-1</measure>
    <time_frame>0-60 days post fecal transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue histology</measure>
    <time_frame>0-60 days post fecal transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue 16s rDNA</measure>
    <time_frame>0-60 days post fecal transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma metabolomics</measure>
    <time_frame>0-60 days post fecal transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue eosinophils</measure>
    <time_frame>0-60 days post fecal transplant</time_frame>
    <description>single-cell atomic mass spectrometry</description>
  </secondary_outcome>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Clostridium Difficile</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Colon biopsies
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients receiving fecal transplant for recurrent Clostridium difficile infection
        identified from the University of Virginia complicated Clostridium difficile clinic
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  one or more relapse of Clostridium difficile colitis

          -  eligible for fecal microbiota transplant

        Exclusion Criteria:

          -  Unwilling to have biopsies for research conducted at time of FMT

          -  Concurrent participation in another clinical trial, except outcome of FMT study

          -  Clinical contraindication to colonoscopy, FMT, flexible sigmoidoscopy or conscious
             sedation

          -  Pregnancy

          -  Inability to give informed consent

          -  Incarceration

          -  Antibiotics unless discontinued 48 hours prior to FMT

          -  Celiac disease or any other form of inflammatory bowel disease

          -  HIV infection

          -  Neutropenia (&lt;1000 PMNs/Âµl blood)

          -  Concurrent participation in another clinical trial, except outcome of FMT study

          -  Anticoagulants if not able to discontinue 5 days prior to endoscopy and flexible
             sigmoidoscopy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William A. Petri, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>William A. Petri, MD,PhD</last_name>
    <phone>434-924-5621</phone>
    <email>wap3g@virginia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer White, BSN</last_name>
    <phone>434-982-3649</phone>
    <email>jaw9r@virginia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William A. Petri, MD,PhD</last_name>
      <phone>434-924-5621</phone>
      <email>wap3g@virginia.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2016</study_first_submitted>
  <study_first_submitted_qc>June 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2016</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>William Petri, MD</investigator_full_name>
    <investigator_title>Chief, Infectious Diseases &amp; International Health</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

